The recommended management of CRS and ICANS includes anti-cytokine agents such as tocilizumab (IL-6 receptor antagonist), anakinra (IL-1 receptor antagonist), siltuximab (anti-IL-6 mAb), etanercept (TNFα inhibitor), and infliximab (anti-TNFα mAb) [150,151]. The gene discussed is IL6; the disease is congenital rubella syndrome.